FNTB抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P06977(ALOX5 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P06977(ALOX5 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

**Background of FNTB Antibody**

The **Farnesyltransferase Beta Subunit (FNTB)** is a critical enzyme component of farnesyltransferase, which catalyzes the post-translational modification of proteins by attaching farnesyl groups to cysteine residues. This process, known as farnesylation, is essential for membrane localization and activation of signaling proteins like Ras, which play pivotal roles in cell proliferation, survival, and differentiation. Dysregulation of FNTB has been implicated in cancers and neurodegenerative disorders due to its role in Ras pathway activation and improper protein trafficking.

**FNTB antibodies** are immunological tools designed to detect and quantify FNTB expression in research and diagnostic settings. They enable the study of FNTB's involvement in disease mechanisms, particularly in oncogenesis, where aberrant Ras signaling is common. These antibodies are widely used in techniques such as Western blotting, immunohistochemistry, and immunofluorescence to assess protein levels, cellular localization, and interaction partners. Additionally, FNTB antibodies support therapeutic development, as farnesyltransferase inhibitors (FTIs) are explored for targeting Ras-driven cancers. Their specificity and reliability make them crucial for validating FNTB as a biomarker or therapeutic target in preclinical studies.

In summary, FNTB antibodies serve as vital reagents for understanding protein prenylation biology and advancing research into diseases linked to FNTB dysfunction.